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The Starr-Edwards Valve 
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Portland, Oregon 
This report reviews the results obtained with the current 
models of the Silastic ball valve, classifying the experi-
ence with the mitral and aortic models into the periods 
Mitral Model Aortic Model 
6120 1260 
1965 to 1973 to 1965 to 1973 to 
1972 1984 1972 1984 
Number of valves 84 234 133 470 
Follow-up 
Total 783 586 1,318 1,512 
(patient-years) 
Maximum (years) 19 10 19 10 
Complications 
( %/patient-years) 
Embolism 6.0 2.9 4.6 1.8 
Thrombosis 0.6 0.0 0.2 0.0 
All valve failures 1.9 1.2 1.5 1.1 
In the 25 years since prosthetic heart valves became a clin•
ical reality, there has been great improvement in the results 
of heart valve replacement. The current Silastic ball heart 
valves, models 6120 mitral and 1200/1260 aortic, have been 
in continuous use for almost 20 years and thus provide a 
unique opportunity to determine the relative contribution of 
new valve designs as compared with that of other surgical 
and patient-related variables to this improvement. 
Methods 
Clinical material. Data in this ongoing study are ob•
tained in a prospective manner by questionnaires, clinic 
visits and phone inquiries. Information is stored in a Hew•
lett-Packard computer system and analyzed with both stan•
dard statistical software and specially written programs 
(Medical Data Research Center). 
Definitions. Thromboembolism is defined as any sus-
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before and after 1973. 
Valve failure is defined according to the Stanford 
method and includes any valve-related death or com•
plication necessitating valve removal (there have been 
no mechanical failures). Comparison of the valve model 
used today with the same model used in the late 1960s 
shows that the results have improved dramatically, es•
pecially with regard to thromboembolism. The results 
obtained with valves implanted after 1973 compare fa•
vorably with those of other contemporary valves intro•
duced in the early 1970s. 
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pee ted embolic event, peripheral or central, transient or with 
permanent residual deficit, except in patients with preex•
isting disease of the vessels supplying the affected organ. 
An effort is made to maintain all patients on warfarin an•
ticoagulation but inadequate anticoagulation does not ex•
clude a patient from the analysis. We employ the Stanford 
definition of valve failure, that is, any valve-related com•
plication such as infection, embolus, bleeding, thrombosis 
and leak, causing patient death or requiring valve removal. 
The only exclusion is operative death from preexisting bac•
terial endocarditis. 
For comparison with other current prostheses, we have 
used recently published studies (1-32) from major institu•
tions in which adequate statistical assessments were given 
or could be obtained. 
Table 1 summarizes the characteristics of the patients in 
this analysis. Patients with multiple valve replacement are 
excluded, although those with other concomitant proce•
dures, such as coronary bypass surgery or valve repair, are 
included. 
Results and Comparisons 
Linearized rates of thromboembolism, prosthetic throm•
bosis and overall (Stanford) valve failure are given in Table 
0735-1097/85/$3.30 
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Table 1. Patient Data, 1965 to 1984 
Mitral Aortic 
Patients 318 603 
Mean age (years) 54.2 58.9 
Percent male (%) 33 67 
Follow-up 
Completeness (1983 to 1984) (%) 92 93 
Mean (years) 4.3 4.7 
Total (patient-years) 1,368 2,830 
Maximal (years) 19.1 18.5 
2 by the time frame of implantation for both the aortic and 
mitral valve series. There are improved results for valve 
placement in both positions in the current time frame (after 
1973) with regard to all of these complications. 
Thromboembolism. Actuarial thromboembolism-free 
curves for the entire series of patients with mitral and aortic 
valve prostheses since 1965 are shown in Figures 1 and 2, 
respectively. To permit a meaningful comparison with other 
currently used prostheses, most of which were introduced 
into wide clinical use in the last decade, embolus-free curves 
were computed separately for the time frames before and 
after 1973, for valves in both the mitral (Fig. 3) and aortic 
(Fig. 4) positions. These current rates compare favorably 
with those recently published (1-9) for other currently used 
prostheses (Fig. 5 and 6). 
Thrombosis. There have been only seven instances of 
valve thrombosis: five mitral (one fatal) and two aortic (one 
fatal). The time-related rates are 0.4 and 0.1 % per patient•
year, respectively. The rate of thrombosis with various 
prostheses is generally too low to warrant an actuarial anal•
ysis and linearized rates are all that can be obtained. A 
composite analysis for the various types of prostheses taken 
from our report and others is given in Table 3. 
Valve failure. The actuarial failure-free curves for Si•
las tic ball valves in the mitral and aortic positions using the 
modified Stanford definition are shown in Figures 7 and 8 
(solid lines with circles); data on the actuarial percent of 
patients free of fatal valve failure are also indicated (dashed 
lines). Comparative failure-free curves for various valve 
types that also use the Stanford definition of valve failure 
are shown in Figures 9 and 10. 
Table 2. Linearized Valve Complication Rates (%/patient-year) 
Mitral Model 6120 Aortic Model 1260 
1965 to 1973 to 1965 to 1973 to 
1972 1984 1972 1984 
Embolism 6.0 2.9 4.6 1.8 
Thrombosis 0.6 0.0 0.2 0.0 
All valve 1.9 1.2 1.5 1.1 
failures 
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Figure 1. Actuarial thromboembolism-free curve for all isolated 
mitral Silastic ball valves, 1965 to 1984. 
Discussion 
Valve thromboembolism. Thromboembolism rates for 
both the mitral and aortic Silastic ball valves have decreased 
significantly in the past decade compared with the previous 
rates for the same valve models (Fig. 3 and 4). When the 
current rates are compared with the rates for other currently 
used valves, the results for the Silastic ball valve are in the 
average range for the mitral position (Fig. 5) and somewhat 
below average in the aortic position (Fig. 6). 
Valve thrombosis. With regard to thrombosis, again the 
results are better for the Silastic ball valve after 1973 in 
both the mitral and aortic positions (Table 2). For purposes 
of comparison with other valves, however, we combined 
the entire experience with the Silastic valve, because throm•
bosis is a relatively rare event. A review of all the reported 
data (Table 3) indicates that for each valve type thrombosis 
is more frequent in the mitral position, and that for each 
Figure 2. Actuarial thromboembolism-free curve for all isolated 
aortic Silastic ball valves, 1965 to 1984. 
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Figure 3. Thromboembolism by time frame of implantation for 
the mitral ball valves, 1965 to 1972 (dotted line); 1973 to 1984 
(solid line). 
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Figure 4. Thromboembolism by time frame of implantation for 
the aortic ball valve, 1965 to 1972 (dotted line); 1973 to 1984 
(solid line). 
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Figure 5. Comparative thromboembolism-free rates for various 
types of mitral valves. The numbers in the graph correspond to 
the references. 
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Figure 6. Comparative thromboembolism-free rates for various 
types of aortic valves. The numbers in the graph correspond to 
the references. 
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Figure 7. Failure-free curves for mitral Silastic ball valves. Fatal 
plus reoperation (solid line); fatal only (dashed line). 
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Figure 8. Failure-free curves for aortic Silastic ball valves. Fatal 
plus reoperation (solid line); fatal only (dashed line). 
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Table 3. Comparative Thrombosis Rates for Various Valves 
Valve 
Type References 
Mitral position 
Tissue 1,6,11,13-16 
Ball Present series, 
7,22-25 
Disc 5,7,16,19-21, 
23,26,27,29,31 
Aortic position 
Tissue 1,10-15,28 
Ball Present series, 
7,17 
Disc 5,7,10,18-21, 
29,30 
position the disc valve has a significantly higher incidence 
of thrombosis than does the Silastic ball valve, Moreover, 
the occurrence of thrombosis in the disc valve is often sud•
den and catastrophic, whereas with the ball valve there is 
usually a gradual onset of worsening symptoms for several 
months, providing an opportunity for elective replacement 
(33), The tissue valves have a significantly reduced risk of 
thrombosis compared with that of either of the mechanical 
valves, 
Valve failure. The Stanford University group has pro•
posed a definition of valve failure that is general enough to 
provide a comparison between the overall performance of 
tissue valves and mechanical valves, despite differences in 
mode of failure, Although tissue valves have a higher in•
cidence of mechanical primary valve failure, mechanical 
Figure 9. Comparative failure-free rates for various types of mitral 
valves. Present series (solid line); Gabbay et al. (2) (*); Oyer et 
al. (6) (.); Schoen et al. (14) (0); Gallucci et al. (32) (x). 
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No. of Patient- Thrombosis 
Valves Centuries (%/patient-yr) 
2,056 49.1 0.1 
P < 0.001 
1,869 91.5 0.3 
P < 0.001 
2,914 99.1 1.0 
2,995 89.3 0.04 
P < 0.05 
1,441 80.4 0.1 
P < 0.001 
2,221 86.0 0.4 
valves have a higher incidence of complications due to 
anticoagulation, 
The Silastic ball valves in our series have a lower inci•
dence of valve failure after 1973 (Table 2), but the differ•
ences are not significant; thus the entire series is again used 
for the purpose of comparison with other valves, In the 
mitral position, the tissue valves provide a better overall 
result for the first 5 years, the Silastic ball valve is superior 
after 10 years and the curves cross over between 5 and 10 
years (Fig, 9), The newer generation of tissue valves may 
prove to be more durable and thus claim this middle ground, 
but until such a possibility is realized, the Silastic ball valve 
is preferred for a patient with more than a 10 year life 
expectancy, In the aortic position there is no clear difference 
between the two types of valve prostheses (Fig, 10), 
Figure 10. Comparative failure-free rates for aortic valves, Pres•
ent series (solid line); Oyer et al. (12) (.); Schoen et al. (\4) 
(0), 
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